Navigation Links
WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
Date:7/11/2012

SHANGHAI, July 11, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2012 after the New York Stock Exchange closes on Monday, August 13, 2012 (which will be Tuesday morning, August 14, 2012 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, August 14, 2012, to discuss the second-quarter 2012 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004China (Landline):

800-819-0121China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381Conference ID: 10406942A telephone replay will be available two hours after the call's completion at:

United States:

1-866-214-5335China North:

10-800-714-0386China South:

10-800-140-0386Hong Kong:

800-901-596United Kingdom:

0-800-731-7846International:

+61-2-8235-5000Conference ID:

10406942A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com

 


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Third-Quarter 2011 Results
2. WuXi PharmaTech Named a Top Ten Outsourcing Enterprise in China for Five Consecutive Years
3. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
4. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
5. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
6. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
7. ICD-10 Coding Knowledge Assessment Tool Released
8. Verify Brand™ Announces the Release of VB Enterprise 4.0
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
11. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... December 8, 2016 Oxford Gene ... customisable SureSeq™ NGS panel range with the launch of the ... cost-effective study of variants in familial hypercholesterolemia (FH). The panel ... detection on a single small panel and allows customisation by ... includes all exons for LDLR , P ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial ... Technology Awards. uBiome is one of just six company finalists in the Health ... addition to uBiome, companies nominated as finalists in this year’s awards include Google, ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... ), a leading commercial provider of clinically actionable ... cancer patients, announces that clinical data featuring its ... concordance to tissue biopsy for the detection of ... The results from research sponsored by Sara Cannon ...
Breaking Biology Technology:
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
Breaking Biology News(10 mins):